GEN-MKT-18-7897-A
Oct 25, 2016 | Blogs, Technology | 0 comments
The M3 MicroLC System is designed for scientists who are struggling to analyze small volume samples with conventional LC-MS and need to lower their limits of quantitation while maintaining throughput and robustness.
When designing the M3 MicroLC System, we focused on creating an easy-to-use LC that would make microflow LC simple – even for those new to the technique.
With the M3 MicroLC System you can:
We are also pleased to announce that the MicroLC System is the recipient of the 2016 Instrument Business Outlook’s (IBO) Silver Analytical Instrument Industrial Design Award. Each year Instrument Business Outlook (IBO) announces their awards for excellence in the industrial design of analytical instruments, portable analytical instruments, and laboratory equipment. The winners of the 2016 Awards demonstrate how industrial design can improve a product’s functionality and the end user’s experience. Criteria include innovation, aesthetics, functionality and utility. Award candidates are chosen from the new products that IBO monitors through trade shows, trade publications, press releases and the Internet. Read more about this award >
Last year, Technology Networks hosted two webinars that featured groundbreaking research utilizing SWATH DIA (data-independent acquisition) for exposomics and metabolomics. Researchers Dr. Vinicius Verri Hernandes from the University of Vienna and Dr. Cristina Balcells from Imperial College London (ICL) demonstrated how a DIA approach can be successfully implemented in small molecule analysis using the ZenoTOF 7600 system. Their innovative approaches highlight the potential of SWATH DIA to enhance the detection and analysis of chemical exposures and metabolites, paving the way for new insights into environmental health and disease mechanisms.
For as long as PFAS persist in the environment, there is no doubt they will persist in our conversations as environmental scientists. Globally, PFAS contamination has been detected in water supplies, soil and even in the blood of people and wildlife. Different countries are at various stages of addressing PFAS contamination and many governments have set regulatory limits and are working on assessing the extent of contamination, cleaning up affected sites and researching safer alternatives.
On average, it takes 10-15 years and 1-2 billion dollars to approve a new pharmaceutical for clinical use. Since approximately 90% of new drug candidates fail in clinical development, the ability to make early, informed and accurate decisions on the safety and efficacy of new hits and leads is key to increasing the chances of success.
Posted by
You must be logged in to post a comment.
Share this post with your network